Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Cash from Operations: 2011-2025

Historic Cash from Operations for Capricor Therapeutics (CAPR) over the last 15 years, with Sep 2025 value amounting to -$19.7 million.

  • Capricor Therapeutics' Cash from Operations fell 69.11% to -$19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$61.0 million, marking a year-over-year decrease of 65.90%. This contributed to the annual value of -$40.0 million for FY2024, which is 56.25% down from last year.
  • As of Q3 2025, Capricor Therapeutics' Cash from Operations stood at -$19.7 million, which was up 2.15% from -$20.1 million recorded in Q2 2025.
  • Capricor Therapeutics' 5-year Cash from Operations high stood at $24.0 million for Q1 2022, and its period low was -$20.1 million during Q2 2025.
  • In the last 3 years, Capricor Therapeutics' Cash from Operations had a median value of -$11.6 million in 2023 and averaged -$10.2 million.
  • As far as peak fluctuations go, Capricor Therapeutics' Cash from Operations skyrocketed by 822.26% in 2022, and later slumped by 407.20% in 2025.
  • Quarterly analysis of 5 years shows Capricor Therapeutics' Cash from Operations stood at -$5.6 million in 2021, then declined by 22.65% to -$6.9 million in 2022, then plummeted by 67.98% to -$11.6 million in 2023, then declined by 27.62% to -$14.8 million in 2024, then tumbled by 69.11% to -$19.7 million in 2025.
  • Its Cash from Operations stands at -$19.7 million for Q3 2025, versus -$20.1 million for Q2 2025 and -$6.4 million for Q1 2025.